Could I help you?
New Reduced price! PDA TR 57 View larger

PDA TR 57

M00001924

New product

PDA TR 57 Technical Report No. 57 (TR 57) Analytical Method Validation and Transfer for Biotechnology Products

Report / Survey by Parenteral Drug Association, 07/01/2012

More details

In stock

$195.00

-40%

$325.00

More info

Full Description

Similar to the manufacturing process, an analytical method can also be considered a process. The validation strategy for analytical methods could therefore conceptually follow those of Process Validation. As such, Analytical Method Validation (AMV) can be defined as the collection and evaluation of data from the analytical method development stage throughout routine QC testing which establishes scientific evidence that an analytical method is capable of consistently delivering accurate and reliable results. PDA Technical Report No. 57: Analytical Method Validation provides practical and strategic guidance to efficiently use historical data and knowledge to design suitable risk-based AMV studies and to set appropriate protocol acceptance criteria. The document provides an illustrated map of the typical method lifecycle steps prior, during and beyond the AMV studies to help users visualize their AMV program. The typical sequence of all pre-validation, validation and post-validation steps is reflected in the sequence of sections in the technical report. Technical Report No. 57 provides risk-based guidance for the validating methods following their development or qualification. It also contains risk-based guidance for other, related method lifecyle steps, such as Analytical Method Transfer (AMT). The guidance provided builds upon the International Conference on Harmonization (ICH) Q2 (R1) guidelines and includes additional considerations for analytical platform technology (APT) methods as well as the impact of stakeholder considerations, and essentially all modern quality expectations as recommended in the ICH Q8 (R2), Q9 and Q10 guidelines.